Furthermore, HSP90 inhibitor 17-MAG has been indicated as an immune adjuvant in the context of vaccines targeting HSP90 client protein EphA2, reconditioning the tumor microenvironment to enhance patient immune responses. Here, HSP90AB1 is linked to neoplasm.